Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Real-world use of nivolumab in gastric cancer

Yu Sunakawa • 8 Jun 2021
ASCO 2021
Gastric Cancer Gastrointestinal Cancer Nivolumab
DELIVER

Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, discusses the findings of a prospective investigation evaluating clinical outcomes from real-world data of nivolumab treatment in advanced gastric cancer. The real-world data of nivolumab treatment in advanced gastric cancer indicated comparable survival to previous clinical trial data. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Yu Sunakawa, MD, PhD has received grants and personal fees from Taiho Pharmaceutical, Chugai Pharma, Takeda, Eli Lilly Japan, and Sanofi; personal fees from Bayer Yakuhin, Yakult Honsha, Bristol-Myers Squibb Japan, Merck Biopharma, Ono Pharma, MSD, Daiichi Sankyo; and grants from Otsuka.

More from Yu Sunakawa

3:15
Predictive biomarkers for RAS-wt mCRC treated with cetuximab and m-FOLFOXIRI
Yu Sunakawa • 21 Oct 2023
3:01
DEEPER: m-FOLFOXIRI and cetuximab versus bevacizumab in mCRC
Yu Sunakawa • 20 Jan 2023
2:45
1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRC
Yu Sunakawa • 8 Jun 2021
1:04
DEEPER: FOLFOXIRI + cetuximab or bevacizumab for 1L mCRC
Yu Sunakawa • 15 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals